Table 1. Characteristics of study population.
| Characteristics | 35-37yrs | 38-39yrs | 40-42yrs | ≥43yrs | All AMA patients |
| No. of women | 1931 | 772 | 594 | 189 | 3486 |
| No. of cycles | 2442 | 1183 | 1025 | 438 | 5088 |
| BMI (kg/m2) | 21.7±2.7 | 22.2±2.7 | 22.2±2.7 | 22.5±2.8 | 22.0±2.7 |
| <18.5 | 173(9.0) | 47(6.1) | 32(5.4) | 10(5.3) | 262(7.6) |
| 18.5-24.9 | 1528(79.7) | 602(78.4) | 479(81.2) | 146(77.2) | 2755(79.5) |
| ≥25 | 217(11.3) | 119(15.5) | 79(13.4) | 33(17.5) | 448(12.9) |
| Duration of infertility (yrs.) |
5.0 (3.0-8.0) |
6.0 (3.0-10.0) |
5.0 (2.0-10.0) |
4.0 (2.0-9.5) |
5.0 (3.0-9.0) |
| Parity≥1(%) | 397 (20.6) | 220 (28.5) | 225 (37.9) | 102 (54.0) | 944 (27.1) |
| bFSH(IU/L) | 6.3±2.6 | 6.5±3.0 | 7.4±3.7 | 7.9±4.2 | 6.6±3.0 |
| ≤10 | 1808 (93.6) | 711 (92.1) | 505 (85.0) | 145 (76.7) | 3169(90.9) |
| >10 | 123(6.4) | 61 (7.9) | 89 (15.0) | 44 (23.3) | 317 (9.1) |
| bFSH/bLH | 2.2±1.1 | 2.5±1.6 | 2.6±1.2 | 2.7±1.9 | 2.4±1.3 |
| bE2(pmol/L) | 144.2±113.0 | 143.9±88.1 | 154.5±114.9 | 192.3±269.4 | 148.3±122.6 |
| Type of infertility (%) | |||||
| Primary | 780(41.4) | 258 (33.4) | 169 (28.5) | 43 (22.8) | 1270(36.4) |
| Secondary | 1131(58.6) | 514 (66.6) | 425 (71.5) | 146 (77.2) | 2216(63.6) |
| Cause of infertility (%) | |||||
| Unexplained | 17 (0.9) | 6 (0.8) | 5 (0.9) | 2 (1.1) | 30 (0.9) |
| Severe endometriosis | 84 (4.4) | 22 (2.8) | 24 (4.0) | 3 (1.6) | 133 (3.8) |
| Pelvic and tubal factor | 949 (49.1) | 378 (49.0) | 292 (49.2) | 88 (46.6) | 1707(48.9) |
| Ovulatory dysfunction | 24 (1.2) | 8 (1.0) | 9 (1.5) | 7 (3.7) | 48 (1.4) |
| Male factor | 461 (23.9) | 179 (23.2) | 127 (21.4) | 42 (22.2) | 809 (23.2) |
| combined | 396 (20.5) | 179 (23.2) | 137 (23.1) | 47 (24.9) | 759 (21.8) |
| Ovarian reserve | |||||
| Non- POSEIDON | 984(51.0) | 330(42.7) | 159(26.8) | 20(10.6) | 1493(42.8) |
| POSEIDON group 2 | 722(37.4) | 296(38.3) | 228(38.4) | 75(39.7) | 1321(37.9) |
| POSEIDON group 4 | 225(11.7) | 146(18.9) | 207(34.8) | 94(49.7) | 672(19.3) |
| Ovarian stimulation protocol | |||||
| GnRH long agonist | 1972(80.8) | 812(68.6) | 522(51.0) | 126(28.6) | 3432(67.5) |
| GnRH antagonist Minimal stimulation |
178(7.3) | 143(12.1) | 185(18.1) | 120(27.3) | 626(12.3) |
| 72(2.9) | 52(4.4) | 84(8.2) | 84(19.1) | 292(5.7) | |
| GnRH short agonist | 171(7.0) | 152(12.8) | 205(20.0) | 99(22.5) | 627(12.3) |
| others | 49(2.0) | 24(2.0) | 27(2.6) | 11(2.5) | 111(2.2) |
| Treatment protocol (%) | |||||
| IVF | 1648(67.5) | 790 (66.8) | 695 (68.0) | 276(62.7) | 3409(67.0) |
| ICSI | 794(32.5) | 393 (33.2) | 327 (32.0) | 164 (37.3) | 1678(33.0) |
| Number of oocytes in the 1st OPU cycle | 11.1±7.4 | 9.5±6.5 | 7.0±5.6 | 4.6±4.3 | 9.7±7.0 |
| Average number of retrieved oocytes | 10.5±7.2 | 9.0±6.3 | 6.5±5.2 | 4.4±4.3 | 8.8±6.8 |
| Number of available embryos in the 1st OPU cycle | 4.5±3.4 | 3.8±2.9 | 3.0±2.4 | 2.1±1.8 | 4.0±3.2 |
| Average number of available embryos | 4.3±3.3 | 3.6±2.7 | 2.8±2.3 | 2.0±1.8 | 3.6±3.0 |
Data are presented as mean ± SD, median (IQR) and n (%). AMA, advanced maternal age; BMI, body mass index; bFSH, basal follicle stimulating hormone; bLH, basal luteinizing hormone; bE2, basal estradiol; IVF, in-vitro fertilization; ICSI, intracytoplasmic sperm injection; OPU, Ovum Pick-up.